Welcome to our dedicated page for Transcode Therapeutics SEC filings (Ticker: RNAZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating critical details in TransCode Therapeutics’ SEC paperwork can feel like decoding a genetic sequence. Early-stage oncology companies pack their 10-K with pages on RNA manufacturing risks, cash runway projections, and microRNA-10b clinical data—information investors need yet rarely have time to sift through.
Stock Titan solves this problem. Our AI reads every TransCode Therapeutics annual report 10-K simplified, each quarterly earnings report 10-Q filing, and all 8-K material events explained the moment they hit EDGAR. It then delivers plain-English summaries, key financial metrics, and red-flag alerts so you can understand TransCode’s pipeline progress and funding plans without poring over technical jargon. Need to monitor TransCode Therapeutics insider trading Form 4 transactions? Real-time dashboards surface every Form 4 insider transactions the second executives buy or sell shares.
Here’s what you’ll uncover:
- Trial readouts and R&D spend from the latest earnings report filing analysis
- Equity offerings, collaboration revenue, and cash burn trends in the 10-Q
- Board proposals and proxy statement executive compensation details
- Immediate alerts on financings or clinical holds via 8-K postings
- TransCode Therapeutics executive stock transactions Form 4 with historical charts
Whether you Google “TransCode Therapeutics SEC filings explained simply” or ask an AI assistant “How to read TransCode’s 10-K?”, this page delivers. Our expert commentary, AI-powered extraction, and complete, continuously updated database ensure you make informed decisions faster. Stop scrolling through 200-page PDFs—start understanding TransCode Therapeutics SEC documents with AI today.
TransCode Therapeutics (RNAZ) filed Amendment No. 2 to report the effective date of its Contingent Value Rights Agreement and a change in rights agent.
Effective October 8, 2025, TransCode entered a CVR Agreement with Vstock Transfer, LLC as rights agent. Each holder of common stock as of 5:00 p.m. Eastern Time on October 20, 2025 is entitled to one CVR per share, subject to the agreement’s terms. Each CVR entitles holders, in the aggregate, to
The rights agent and holders of at least
TransCode Therapeutics (RNAZ) reported via Form 8-K that it issued a press release announcing completion of its Phase 1a clinical trial with its lead candidate, TTX‑MC138. The company attached the press release as Exhibit 99.1 and a related scientific poster as Exhibit 99.2.
The filing includes forward‑looking statements related to potential future trials, regulatory submissions, intellectual property, competition, third‑party dependencies, and broader macro risks. It also references risks tied to funding needs and the company’s ability to continue as a going concern, directing readers to the latest Form 10‑K risk factors for additional detail.
TransCode Therapeutics, Inc. Schedule 13G/A filed by Anson-related parties reports collective beneficial ownership of 27,125 shares of TransCode common stock, representing 0.1% of the outstanding class when including shares underlying warrants. The reporting group includes Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and principals Tony Moore, Amin Nathoo and Moez Kassam, with shared voting and dispositive power over the 27,125 shares and no sole voting or dispositive power reported. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control of the issuer.
TransCode Therapeutics, Inc. is the subject of a Schedule 13G reporting that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC together beneficially hold 49,018 shares, representing 5.9% of the outstanding common stock. The filing shows no sole voting or dispositive power and records shared voting and shared dispositive power for the reported shares, indicating the position is held collectively rather than controlled by a single entity.
The filing includes a joint filing agreement and an exhibit identifying the subsidiary that acquired the securities, and it contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
FAQ
What is the current stock price of Transcode Therapeutics (RNAZ)?
What is the market cap of Transcode Therapeutics (RNAZ)?
